TW483757B - A pharmceutical formulation containing melatonin for use in treating preventing symptoms of dependence on, tolerance of, or addiction to benzodiazepine drugs - Google Patents

A pharmceutical formulation containing melatonin for use in treating preventing symptoms of dependence on, tolerance of, or addiction to benzodiazepine drugs Download PDF

Info

Publication number
TW483757B
TW483757B TW085104319A TW85104319A TW483757B TW 483757 B TW483757 B TW 483757B TW 085104319 A TW085104319 A TW 085104319A TW 85104319 A TW85104319 A TW 85104319A TW 483757 B TW483757 B TW 483757B
Authority
TW
Taiwan
Prior art keywords
melatonin
benzodiazepine
patients
treatment
pharmaceutical composition
Prior art date
Application number
TW085104319A
Other languages
English (en)
Chinese (zh)
Inventor
Nava Zisapel
Original Assignee
Neurim Pharma 1991
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/381,535 external-priority patent/US6469044B1/en
Application filed by Neurim Pharma 1991 filed Critical Neurim Pharma 1991
Application granted granted Critical
Publication of TW483757B publication Critical patent/TW483757B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TW085104319A 1995-02-01 1996-04-12 A pharmceutical formulation containing melatonin for use in treating preventing symptoms of dependence on, tolerance of, or addiction to benzodiazepine drugs TW483757B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/381,535 US6469044B1 (en) 1995-02-01 1995-02-01 Method for treating patients suffering from drug dependencies which lead to plasma melationin deficiencies
EP95303853A EP0724878B1 (en) 1995-02-01 1995-06-06 Use of melatonin for treating patients suffering from drug dependencies

Publications (1)

Publication Number Publication Date
TW483757B true TW483757B (en) 2002-04-21

Family

ID=26140195

Family Applications (1)

Application Number Title Priority Date Filing Date
TW085104319A TW483757B (en) 1995-02-01 1996-04-12 A pharmceutical formulation containing melatonin for use in treating preventing symptoms of dependence on, tolerance of, or addiction to benzodiazepine drugs

Country Status (22)

Country Link
JP (1) JP4516159B2 (lv)
CN (1) CN1083263C (lv)
AT (1) AT408188B (lv)
AU (1) AU695366B2 (lv)
BG (1) BG62876B1 (lv)
BR (1) BR9607169A (lv)
CZ (1) CZ291349B6 (lv)
DK (1) DK176081B1 (lv)
EE (1) EE03384B1 (lv)
FI (1) FI119586B (lv)
IS (1) IS1980B (lv)
LU (1) LU90118B1 (lv)
LV (1) LV11940B (lv)
MD (1) MD1716C2 (lv)
NO (1) NO312814B1 (lv)
NZ (1) NZ298878A (lv)
PL (1) PL183148B1 (lv)
SI (1) SI9620022A (lv)
SK (1) SK284521B6 (lv)
TR (1) TR199700723T1 (lv)
TW (1) TW483757B (lv)
WO (1) WO1996023496A1 (lv)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU227002B1 (en) 2000-01-05 2010-04-28 Neurim Pharma 1991 Use of melatonin in the manufacture of controlled release medicament for the prevention or treatment of symptoms of hypertension
IL149377A (en) * 2002-04-28 2012-10-31 Neurim Pharma 1991 Pharmaceutical formulation comprising melatonin for the potentiation of the effect of hypnotic compounds
IL155666A (en) 2003-04-29 2013-12-31 Neurim Pharma 1991 Insomnia treatment
US9119846B2 (en) 2003-04-29 2015-09-01 Neurim Pharmaceuticals (1991) Ltd. Method and composition for enhancing cognition in alzheimer's patients
ES2646197T3 (es) 2012-01-26 2017-12-12 Vanda Pharmaceuticals Inc. Tratamiento de trastornos del ritmo circadiano
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
WO2014100292A1 (en) 2012-12-18 2014-06-26 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
US11090285B2 (en) 2013-11-12 2021-08-17 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
CN109922795B (zh) * 2016-10-31 2021-10-08 纽里姆药物有限公司 褪黑素小片剂及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122007000073I1 (de) * 1991-05-09 2008-01-31 Neurim Pharma 1991 Melatonin enthaltene Arzneimittel
IT1251544B (it) * 1991-05-13 1995-05-17 Gabriele Biella Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico

Also Published As

Publication number Publication date
JPH10513177A (ja) 1998-12-15
SI9620022A (sl) 1998-10-31
CN1083263C (zh) 2002-04-24
ATA901396A (de) 2001-02-15
PL183148B1 (pl) 2002-05-31
DK176081B1 (da) 2006-04-18
CZ240597A3 (cs) 1998-01-14
SK103097A3 (en) 1998-01-14
JP4516159B2 (ja) 2010-08-04
AU695366B2 (en) 1998-08-13
MX9705856A (es) 1998-07-31
FI119586B (fi) 2009-01-15
NO312814B1 (no) 2002-07-08
EE9700166A (et) 1998-02-16
CN1172431A (zh) 1998-02-04
MD970254A (en) 1999-05-31
IS1980B (is) 2005-01-14
MD1716B2 (en) 2001-08-31
CZ291349B6 (cs) 2003-02-12
LV11940A (lv) 1998-01-20
BR9607169A (pt) 1997-11-11
BG101803A (en) 1998-04-30
AU4457496A (en) 1996-08-21
TR199700723T1 (xx) 1998-02-21
NO973531D0 (no) 1997-07-31
NZ298878A (en) 1999-05-28
EE03384B1 (et) 2001-04-16
PL321630A1 (en) 1997-12-08
FI973185A0 (fi) 1997-07-31
FI973185A (fi) 1997-09-30
MD1716C2 (ro) 2002-02-28
IS4532A (is) 1997-07-25
BG62876B1 (bg) 2000-10-31
LV11940B (lv) 1998-05-20
DK89697A (da) 1997-07-30
AT408188B (de) 2001-09-25
WO1996023496A1 (en) 1996-08-08
SK284521B6 (sk) 2005-05-05
LU90118B1 (fr) 1997-11-13
NO973531L (no) 1997-09-30

Similar Documents

Publication Publication Date Title
KR100425045B1 (ko) 약물중독의치료를위한멜라토닌함유약학적조성물
TW483757B (en) A pharmceutical formulation containing melatonin for use in treating preventing symptoms of dependence on, tolerance of, or addiction to benzodiazepine drugs
EP1272177B1 (en) Method and formulation for treating resistance to antihypertensives and related conditions
KR101000624B1 (ko) 멜라토닌을 포함하는 약제학적 제제
US6344487B1 (en) Treatment of insomnia
Pagot et al. Comparison of the efficacy and tolerability of zolpidem 20 mg and triazolam 0.5 mg in anxious or depressed insomniac patients
CA2211839C (en) Use of melatonin for treating patients suffering from drug addiction
MXPA97005856A (en) Use of melatonine in the manufacture of unmedicament to deal with addiction to dro
Potgieter Overview of clinical studies for acamprosate

Legal Events

Date Code Title Description
GD4A Issue of patent certificate for granted invention patent
MK4A Expiration of patent term of an invention patent